Tag
Emerging evidence identifies a bidirectional link between breast cancer and pulmonary arterial hypertension (PAH) driven by BMPR2 signaling and IL-1β-mediated inflammation. This study suggests breast cancer may serve as a critical second hi
The phase 3 SONIA trial demonstrates that initiating CDK4/6 inhibitors in the first-line setting does not improve overall survival compared to second-line use in HR-positive, ERBB2-negative advanced breast cancer, while significantly increa
A prospective study reveals that PM2.5 and ozone exposure significantly exacerbate cardiac dysfunction and adverse remodeling in breast cancer patients receiving anthracyclines or trastuzumab, doubling the risk of clinical LVEF decline.
A massive 21-country study confirms that mammography screening has significantly shifted breast cancer detection toward earlier stages, contributing to a substantial decline in mortality across Europe, though treatment advances also play a
The PHENOMENAL phase 2 study reveals that liposomal irinotecan (nal-IRI) achieves a 22% intracranial objective response rate in patients with HER2-negative breast cancer and brain metastases, addressing a critical unmet need in neuro-oncolo
Researchers have developed a machine learning model using real-world and clinical trial data to predict distant recurrence risk and ribociclib’s therapeutic effect in HR+/HER2- early breast cancer, offering a potential tool for person
The DESTINY-Breast08 phase 1b study demonstrates that trastuzumab deruxtecan (T-DXd) combined with chemotherapy, AKT inhibitors, or endocrine therapy is manageable and clinically active in HER2-low metastatic breast cancer, offering new pat
The Phase II SOLTI-1303 PATRICIA trial (Cohort C) demonstrates that a triplet regimen of palbociclib, trastuzumab, and endocrine therapy significantly improves progression-free survival compared to physician’s choice treatments in pre
The CARABELA trial suggests that while neoadjuvant abemaciclib plus letrozole did not meet the threshold for similarity to chemotherapy in highly proliferative HR+/HER2- breast cancer, it remains a viable alternative for patients with lower
A multi-omics analysis from the AURORA program reveals that metastatic breast cancer carries a significantly higher burden of gene fusions than primary tumors. Acquired fusions, particularly involving ESR1, are linked to genomic instability
Explore the Phase 3 TROPION-Breast01 study results, detailing how the antibody-drug conjugate datopotamab deruxtecan offers a superior alternative to standard chemotherapy in advanced HR+/HER2- breast cancer through improved progression-fre
The Phase II TRADE trial demonstrates that a stepwise dose escalation of abemaciclib significantly improves drug tolerability and reduces early discontinuation rates in patients with high-risk HR-positive, HER2-negative early breast cancer
This systematic review and network meta-analysis of 20 randomized trials demonstrate that molecular profiling for ESR1 and PI3K-AKT-PTEN alterations is essential for optimizing endocrine-based strategies after CDK4/6 inhibitor progression,
A longitudinal study of 1,733 Black breast cancer survivors reveals that high intake of ultra-processed foods significantly increases both breast cancer-specific and all-cause mortality, highlighting a critical modifiable risk factor for ad
The Phase 2b PIONEER trial reveals that adding megestrol to letrozole significantly reduces tumor proliferation in early-stage ER+ breast cancer. By reprogramming estrogen receptor activity, this combination offers a dual benefit of enhance
The WSG-KEYRICHED-1 trial investigates a chemotherapy-free regimen for HER2-enriched early breast cancer, showing that 47% of patients achieved a pathological complete response using only immunotherapy and dual HER2 blockade.
The OPBC-07/microNAC study suggests that axillary lymph node dissection can be safely omitted in many breast cancer patients with residual micrometastases post-neoadjuvant chemotherapy, provided nodal radiotherapy is used, though triple-neg
A secondary analysis of the RxPONDER trial finds chemoendocrine therapy causes more lasting cognitive impairment than endocrine therapy alone in both pre- and postmenopausal women.
The WISDOM trial found that 3.1% of women without breast cancer carried pathogenic variants in key susceptibility genes, many outside existing testing guidelines.
A 7‑year follow-up of 2,153 women in the ABC‑DO cohort shows poor breast cancer survival in much of sub‑Saharan Africa, with 5‑year crude survival 40% and marked between-country and racial disparities; reaching WHO stage downstaging targets
